During the early years of the COVID-19 pandemic, experts worried that disruptions to cancer diagnosis and treatment would cost lives. A new study suggests...
The renewable-energy company maintained its two-year outlook despite hefty impairments and tariff costs hitting the company’s bottom line in 2025.
Source link